Purchase Report

Report Name : Japan Biosimilars- Landscape Today Outlook Tomorrow “Biosame” entry, uninterrupted supply and companies’ strong front-end footprint requirement makes it distinct - After a decade, JP Biosimilar guidelines’s first revision expected in FY2020 – Demonstrate Chuikyo need of biosimilar tool to curb healthcare cost - Biosimilars uptake varies as per each opportunity, Remicade BS vs. Rituxan BS – Two poles of the curve - A few skipping NHI listing due to manufacturing issues associated with constant supply need, mature CMO in Japan has potential to fulfill this requirement

* Required Information
Single User: US $ 4500  US $ 3600 Corporate User: US $ 13500  US $ 10800

We are on:

Buy Any Report Avail 20% Discount. Coupon Code: OCT20